Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATHWAY: Parsaclisib in Primary Warm Autoimmune Hemolytic Anemia
jRCT2051210140Phase 3Suspended
- Sponsor
- Incyte
- Start
- Mar 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in warm autoimmune hemolytic anemia (wAIHA) comparing Parsaclisib with Placebo (2 arms). Primary endpoint: Durable hemoglobin response. Started Mar 2022; status: suspended.
02
Drugs
parsaclisib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on jRCT2051210140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210140.